Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepat… Read more
Assembly Biosciences Inc (ASMB) - Total Assets
Latest total assets as of September 2025: $240.00 Million USD
Based on the latest financial reports, Assembly Biosciences Inc (ASMB) holds total assets worth $240.00 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Assembly Biosciences Inc - Total Assets Trend (2008–2024)
This chart illustrates how Assembly Biosciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Assembly Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Assembly Biosciences Inc's total assets of $240.00 Million consist of 96.9% current assets and 3.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.2% |
| Accounts Receivable | $400.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Assembly Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Assembly Biosciences Inc's current assets represent 96.9% of total assets in 2024, an increase from 94.3% in 2008.
- Cash Position: Cash and equivalents constituted 32.2% of total assets in 2024, up from 1.8% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Assembly Biosciences Inc Competitors by Total Assets
Key competitors of Assembly Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Assembly Biosciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Assembly Biosciences Inc generates 0.24x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Assembly Biosciences Inc is currently not profitable relative to its asset base.
Assembly Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.44 | 2.36 | 9.19 |
| Quick Ratio | 4.44 | 2.36 | 9.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $183.43 Million | $ 56.58 Million | $ 200.06 Million |
Assembly Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Assembly Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.53 |
| Latest Market Cap to Assets Ratio | 1.79 |
| Asset Growth Rate (YoY) | -12.9% |
| Total Assets | $119.17 Million |
| Market Capitalization | $212.78 Million USD |
Valuation Analysis
Above Book Valuation: The market values Assembly Biosciences Inc's assets above their book value (1.79 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Assembly Biosciences Inc's assets decreased by 12.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Assembly Biosciences Inc (2008–2024)
The table below shows the annual total assets of Assembly Biosciences Inc from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $119.17 Million | -12.90% |
| 2023-12-31 | $136.82 Million | +34.41% |
| 2022-12-31 | $101.79 Million | -46.72% |
| 2021-12-31 | $191.06 Million | -32.55% |
| 2020-12-31 | $283.25 Million | -18.58% |
| 2019-12-31 | $347.89 Million | +29.79% |
| 2018-12-31 | $268.05 Million | +58.32% |
| 2017-12-31 | $169.30 Million | +72.55% |
| 2016-12-31 | $98.12 Million | -26.64% |
| 2015-12-31 | $133.74 Million | +87.78% |
| 2014-12-31 | $71.23 Million | +162.51% |
| 2013-12-31 | $27.13 Million | +31.99% |
| 2012-12-31 | $20.56 Million | -44.51% |
| 2011-12-31 | $37.05 Million | +153.45% |
| 2010-12-31 | $14.62 Million | +8691.73% |
| 2009-12-31 | $166.25K | -80.90% |
| 2008-12-31 | $870.39K | -- |